RxDoctor Payments Data

Hayah Kassis-George, MD

Cardiovascular Disease · Pittsburgh, PANPI 1508182411

Payments from drug & device makers

$85,438in general payments, 2019–2025

Across 227 payments — averaging $376.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$24K
  • Scpharmaceuticals Inc.$22K
  • United Therapeutics Corporation$16K
  • Janssen Research & Development, LLC$13K
  • Merck$4K
  • Novartis$2K
  • plus $3K from 20 others

What the payments were for

  • Speaking & faculty fees$41,65083%
  • Travel & lodging$1,0932%
  • Food & beverage$6,75714%
  • Education$3811%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,438 in reported general payments places this provider in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$73,233
Medicare patients
172
Services billed
696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag39$895,778
OpsumitMacitentan42$529,838
WinrevairSotatercept-Csrk27$493,497
Tyvaso DpiTreprostinil16$376,619
VyndamaxTafamidis17$368,643
EntrestoSacubitril/Valsartan258$284,122
AdempasRiociguat18$253,985
Bosentan22$218,790
JardianceEmpagliflozin208$212,839
EliquisApixaban189$179,611
Ambrisentan37$104,806
FarxigaDapagliflozin Propanediol86$93,696
Tadalafil26$63,529
XareltoRivaroxaban16$24,952
VerquvoVericiguat25$20,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Bosentan$674$1,644,406103 claims
PfizerVyndamax, Eliquis$139$548,254206 claims
MerckWinrevair, Verquvo$4,443$514,02052 claims
NovartisEntresto$1,761$284,122258 claims
BayerAdempas$389$253,98518 claims
Boehringer IngelheimJardiance$101$212,839208 claims
AstraZenecaFarxiga, Brilinta$569$102,61799 claims
Johnson & JohnsonXarelto$100$24,95216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →